Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

MHRA approves argenx’s subcutaneous generalised myasthenia gravis therapy

Vyvgart is now authorised in the UK for both intravenous and subcutaneous administration

- PMLiVE

GSK shares positive results for Blenrep combination in head-to-head multiple myeloma study

Approximately 176,000 new cases of multiple myeloma are diagnosed globally each year

- PMLiVE

Johnson & Johnson’s nipocalimab shows promise in autoimmune disorder studies

The drug is currently being evaluated in patients with gMG and Sjögren’s disease

- PMLiVE

How user research will help you create better digital products, whatever stage you’re at

User research provides valuable insight that will help you create better digital products and services, whatever stage you’re at.

Graphite Digital

- PMLiVE

Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs

Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.

Avalere Health

- PMLiVE

Valneva sells FDA priority review voucher for chikungunya vaccine for $103m

The company received a tropical disease PRV in November following the FDA’s approval of Ixchiq for the prevention of disease caused by chikungunya virus

- PMLiVE

Novartis expands oncology pipeline with €2.7bn MorphoSys acquisition

The deal includes an investigational therapy being evaluated in myelofibrosis

- PMLiVE

WHO reveals growing global cancer burden in line with World Cancer Day

The three most commonly occurring cancers in 2022 were lung, breast and colorectal cancer

- PMLiVE

How does funding flow in NHSE Regions? – Live Webinar

On Friday 23rd February at 2.00pm, we will sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion...

Petauri Evidence

- PMLiVE

Patient Recruitment & Retention Strategies in the 2024 Clinical Trial Landscape

In the landscape of the clinical trial industry in 2024, persistent challenges persist in the realms of patient recruitment and retention.

- PMLiVE

Takeda gains rights to Protagonist’s blood disorder asset in deal worth over $300m

Rusfertide is currently being evaluated in a phase 3 clinical trial to treat polycythaemia vera

dengue fever mosquito

Positive efficacy results for R21/Matrix-M malaria vaccine published in The Lancet

R21 was added to the World Health Organization's list of prequalified vaccines in December

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links